Anti-MLH1 Antibody (R3K38)

Catalog No.

RHE27605

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000

Target

COCA2, DNA mismatch repair protein Mlh1, MutL protein homolog 1, MLH1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P40692

Applications

ELISA, FCM, IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3K38

[Microsatellite instability as a possible diagnostic marker of the gastric mucosa dysplasia]., PMID:40531552

T cell and autoantibody recognition of nucleus-associated islet autoantigens in individuals with type 1 diabetes., PMID:40490584

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report., PMID:40470107

Detecting microsatellite instability in cancer via multiplexed orthogonal gap-enhanced Raman tags., PMID:40386153

A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses., PMID:40334308

Microsatellite Status, Tumor Budding, CD3 and CD8 T Cell Densities in Relation to Invasiveness, Lymph Node Involvement in Colorectal Adenocarcinoma., PMID:40263681

Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency., PMID:40210796

Immunohistochemical insights into the pathogenesis of colonic sessile serrated lesions., PMID:40135194

Microsatellite-high intrahepatic cholangiocarcinoma with favorable treatment outcome using pembrolizumab., PMID:40032770

[A Case of an Elderly Patient with Advanced Gastric Cancer, Who Underwent Safe Multimodality Treatment with Neoadjuvant Chemotherapy, Minimally Invasive Surgery, and Nivolumab]., PMID:39948967

Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy., PMID:39932790

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054

[Application of PMS2 and MSH6 double-antibody detection in screening of mismatch repair deficient tumors]., PMID:39863527

Intraoperative rapid immunohistochemistry of microsatellite instability using non-contact alternating current electric field mixing., PMID:39443409

Single Center Characterization of a Cohort of Salivary Gland Carcinomas., PMID:39337873

FOXP3+ regulatory T cells, mismatch repair proteins and BRAF V600E status in young-onset colorectal cancer., PMID:39207001

Universal testing in endometrial cancer in Sweden., PMID:39175077

Intriguing Insights From 100 Consecutive Colorectal Cancer Cases in Mid-Kerala: Sparse BRAF Gene Mutations and Mismatch Repair Deficiency (MMR-D)., PMID:39119381

Mismatch repair deficiency: how reliable is the two-antibody approach? A national real-life study., PMID:38859771

Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining., PMID:38802933

Assessing Mismatch Repair Expression by Immunohistochemistry in Colorectal Adenocarcinoma -Insight from a Tertiary Care Centre., PMID:38774931

Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers., PMID:38725237

The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in Colorectal Adenocarcinoma., PMID:38684491

Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer., PMID:38663028

[Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status]., PMID:38591901

HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring., PMID:38436360

Clinicopathological features and evaluation of microsatellite stability of colorectal carcinoma with cribriform comedo pattern., PMID:38394410

The DNA helicase FANCJ (BRIP1) functions in double strand break repair processing, but not crossover formation during prophase I of meiosis in male mice., PMID:38377115

Next-generation sequencing and immunohistochemistry approaches for microsatellite instability detection in endometrial cancer., PMID:38279425

The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma., PMID:38173349

Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy., PMID:38101452

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas., PMID:38029026

Deficient Mismatch Repair Proteins in Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasm: A Rare Case Report., PMID:37900850

The DNA helicase FANCJ (BRIP1) functions in Double Strand Break repair processing, but not crossover formation during Prophase I of meiosis in male mice., PMID:37873301

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)., PMID:37819940

Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters., PMID:37664303

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays., PMID:37623510

Early-Onset/Young-Onset Colorectal Carcinoma: A Comparative Analysis of Morphological Features and Biomarker Profile., PMID:37621838

Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature., PMID:37386324

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration., PMID:37354330

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy., PMID:37202799

The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes., PMID:37060883

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors., PMID:37055532

[Microsatellite instability in gastric cancer is a predictor of a favorable prognosis]., PMID:36469712

Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma., PMID:36440057

Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer., PMID:36276483

Potential of six-transmembrane epithelial antigen of the prostate 4 as a prognostic marker for colorectal cancer., PMID:36187390

Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation., PMID:36128324

Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis., PMID:36104536

An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma., PMID:36051725

Document Download

Anti-MLH1 Antibody (R3K38).pdf